Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yingbin Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6110-0185; OpenAlex author ID A5100711274. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  2. Quercetin liposomes conjugated with hyaluronidase: An efficient drug delivery system to block pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2025.113642↗
  3. Pancreatic cancer environment: from patient-derived models to single-cell omics. Last author DOI 10.1039/d3mo00250k↗
  4. Encoded Fusion-Mediated MicroRNA Signature Profiling of Tumor-Derived Extracellular Vesicles for Pancreatic Cancer Diagnosis. Co-author DOI 10.1021/acs.analchem.3c00929↗
  5. Dual Tumor Exosome Biomarker Co-recognitions Based Nanoliquid Biopsy for the Accurate Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1021/acsnano.3c00674↗
  6. Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2023.1074445↗
  7. Pancreatic cancer incidence and mortality trends in urban Shanghai, China from 1973 to 2017: a joinpoint regression and age-period-cohort analysis. Co-author DOI 10.3389/fonc.2023.1113301↗
  8. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  9. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  10. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Co-author DOI 10.3389/fimmu.2022.983116↗
  11. An Overview of Epigenetic Methylation in Pancreatic Cancer Progression. Last author DOI 10.3389/fonc.2022.854773↗
  12. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma ce… Co-author PMID 33520371↗
  13. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0486-z↗
  14. Author Correction: piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0520-1↗
  15. Correction: KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis Co-author DOI 10.1158/0008-5472.can-20-2503↗
  16. ZFX Promotes Proliferation and Metastasis of Pancreatic Cancer Cells via the MAPK Pathway. Last author DOI 10.1159/000491727↗
  17. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-16-1898↗
  18. Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer. Co-author DOI 10.1016/j.molcel.2016.09.028↗
  19. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis. Last author DOI 10.1007/s13277-013-0671-9↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 4 shared papers, 2022–2026 · strength 0.63
  2. Yan‐Miao Huo · 2 shared papers, 2022–2026 · strength 0.41
  3. Peng Yuan · 4 shared papers, 2017–2020 · strength 0.35
  4. Yefei Rong · 4 shared papers, 2017–2020 · strength 0.35
  5. Mo‐Fang Liu · 4 shared papers, 2017–2020 · strength 0.35
  6. Wenhui Lou · 3 shared papers, 2020 · strength 0.29
  7. Hong Li · 1 shared paper, 2026 · strength 0.26
  8. Jian‐Yu Yang · 1 shared paper, 2026 · strength 0.26
  9. Zong‐Hao Duan · 1 shared paper, 2026 · strength 0.26
  10. Junfeng Zhang · 1 shared paper, 2026 · strength 0.26
  11. Minwei Yang · 1 shared paper, 2026 · strength 0.26
  12. Xianming Kong · 1 shared paper, 2025 · strength 0.25
  13. Ge Sun · 1 shared paper, 2025 · strength 0.25
  14. Ao Gu · 1 shared paper, 2024 · strength 0.23
  15. Mengyao Li · 1 shared paper, 2024 · strength 0.23
  16. Yijue Zhang · 1 shared paper, 2023 · strength 0.22
  17. Tao Chen · 1 shared paper, 2023 · strength 0.22
  18. Xinsen Xu · 1 shared paper, 2023 · strength 0.22
  19. Zhiguo Yu · 1 shared paper, 2023 · strength 0.22
  20. Xiaohua Qian · 1 shared paper, 2023 · strength 0.22
  21. Jianlin Shi · 1 shared paper, 2023 · strength 0.22
  22. Feng Jiao · 2 shared papers, 2022 · strength 0.22
  23. Xiaofei Zhang · 2 shared papers, 2022 · strength 0.22
  24. Tiebo Mao · 2 shared papers, 2022 · strength 0.22
  25. Jiong Hu · 2 shared papers, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.